Profile data is unavailable for this security.
About the company
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
- Revenue in SEK (TTM)5.68m
- Net income in SEK-157.30m
- Incorporated2013
- Employees28.00
- LocationIRLAB Therapeutics ABArvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317573800
- Websitehttps://irlab.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saniona AB | 20.71m | -83.30m | 459.41m | 23.00 | -- | 16.85 | -- | 22.18 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Hamlet BioPharma AB | 0.00 | -33.41m | 479.12m | 7.00 | -- | 8.28 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Initiator Pharma A/S | 0.00 | -33.99m | 546.78m | 3.00 | -- | 16.22 | -- | -- | -0.6243 | -0.6243 | 0.00 | 0.637 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 572.16m | 18.00 | -- | 6.82 | -- | 12.10 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Promimic AB | 39.53m | -9.38m | 623.15m | 17.00 | -- | 8.54 | -- | 15.76 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Gentian Diagnostics ASA | 139.84m | -5.74m | 682.38m | 58.00 | -- | 4.58 | 193.86 | 4.88 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| IRLAB Therapeutics AB | 5.68m | -157.30m | 717.27m | 28.00 | -- | 9.36 | -- | 126.32 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Intellego Technologies AB | 223.23m | 81.38m | 719.43m | 62.00 | 8.89 | 3.70 | 8.38 | 3.22 | 3.07 | 3.07 | 8.53 | 7.39 | 0.9087 | 5.24 | 2.82 | 3,600,549.00 | 33.13 | -- | 46.94 | -- | 68.45 | -- | 36.46 | -- | 2.13 | 7.89 | 0.1833 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Oncopeptides AB | 39.17m | -245.79m | 725.93m | 62.00 | -- | -- | -- | 18.53 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Moberg Pharma AB (publ) | 820.00k | -22.56m | 744.28m | 9.00 | -- | 1.21 | -- | 907.65 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Nightingale Health Oyj | 41.11m | -203.18m | 750.41m | 81.00 | -- | 1.14 | -- | 18.25 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Orexo AB | 619.10m | -73.40m | 789.67m | 113.00 | -- | 12.76 | 136.15 | 1.28 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Alligator Bioscience AB | 55.49m | -248.80m | 864.16m | 55.00 | -- | -- | -- | 15.57 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Cantargia AB | 0.00 | -241.07m | 897.49m | 23.00 | -- | 6.75 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7239 | 0.00 | -- | -- | 0.00 | -83.14 | -55.08 | -107.52 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| BioPorto A/S | 48.84m | -81.18m | 964.36m | 27.00 | -- | 15.33 | -- | 19.75 | -0.1501 | -0.1501 | 0.0903 | 0.1099 | 0.4132 | 3.66 | 7.33 | 1,044,452.00 | -68.68 | -71.10 | -100.20 | -96.55 | 68.08 | 63.38 | -166.23 | -239.22 | 2.36 | -- | 0.1354 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
Data as of Jun 14 2024. Currency figures normalised to IRLAB Therapeutics AB's reporting currency: Swedish Krona SEK
16.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 29 Aug 2023 | 3.50m | 6.75% |
| Unionen (Investment Management)as of 29 Aug 2023 | 2.00m | 3.86% |
| Tredje AP-fondenas of 31 Dec 2022 | 1.85m | 3.57% |
| Andra AP-fondenas of 31 Dec 2022 | 598.68k | 1.16% |
| Handelsbanken Fonder ABas of 31 May 2024 | 325.88k | 0.63% |
| SEB Investment Management ABas of 30 Apr 2024 | 251.16k | 0.49% |
| FCG Fonder ABas of 31 Dec 2023 | 126.72k | 0.25% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 60.00k | 0.12% |
| Skandia Investment Management ABas of 28 Mar 2024 | 42.32k | 0.08% |
| Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 5.45k | 0.01% |
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
